Skip to main content
. 2013 Jun;15(6):579–590. doi: 10.1593/neo.122054

Figure 5.

Figure 5

Statistically significant correlation between CDC25A overexpression and trastuzumab response. (A) Metastatic cohort of patients. (B) Neoadjuvant cohort of patients. Chi-squared test showed a statistically significant correlation between CDC25A overexpression and trastuzumab response in the metastatic cohort (P = .018), where 90% of patients with CDC25A overexpression showed partial or complete response to trastuzumab, while the 66.7% of CDC25A-negative patients had stable or progressive disease (C). Chi-squared test showed a statistically significant correlation between CDC25A overexpression and trastuzumab response in the neoadjuvant cohort (P = .021), where 100% of patients with CDC25A overexpression showed partial or complete response to trastuzumab (D).